NCT04310709View on ClinicalTrials.gov

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

May 30, 2022

Study Completion Date

November 30, 2022

Conditions
Carcinoma, HepatocellularHepatoma
Interventions
DRUG

Regorafenib/Nivolumab

Combination of regorafenib and nivolumab

Trial Locations (3)

Unknown

Bundang CHA Hospital, Seongnam

Samsung Medical Center, Seoul

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Bundang CHA Hospital

OTHER

lead

Asan Medical Center

OTHER

NCT04310709 - Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter